(BAYN) Bayer NA - Overview
Stock: Pharmaceuticals, Consumer Health, Crop Protection, Seeds, Digital Agriculture
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.48% |
| Yield on Cost 5y | 0.22% |
| Yield CAGR 5y | -51.57% |
| Payout Consistency | 87.9% |
| Payout Ratio | 2.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.2% |
| Relative Tail Risk | -16.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.07 |
| Alpha | 115.22 |
| Character TTM | |
|---|---|
| Beta | 0.035 |
| Beta Downside | 0.180 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.85% |
| CAGR/Max DD | -0.10 |
Description: BAYN Bayer NA December 17, 2025
Bayer AG (XETRA:BAYN) is a global life-science group organized into three core segments – Pharmaceuticals, Consumer Health, and Crop Science – that together generate roughly €48 bn of revenue (FY 2023), with an R&D budget of about €6 bn, reflecting its heavy focus on innovation in high-margin drug and seed pipelines.
The Pharmaceuticals division concentrates on prescription medicines for cardiology, women’s health, oncology, hematology, and ophthalmology, and also supplies diagnostic imaging agents and emerging cell- and gene-therapy platforms. The Consumer Health arm sells over-the-counter medicines, nutraceuticals, and medicated skincare, while the Crop Science segment provides chemical and biological crop protection, advanced seeds, digital farming tools, and related services – a market that is currently driven by rising global food demand and tighter environmental regulations, which together are expected to lift the segment’s CAGR to ~5 % through 2028.
Products reach customers via wholesalers, pharmacies, supermarkets, online retailers, hospitals, and directly to farmers. Founded in 1863 and headquartered in Leverkusen, Germany, Bayer leverages its integrated supply chain to cross-sell across its three pillars. For a deeper quantitative assessment, you may want to explore ValueRay’s detailed analyst dashboards.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -198.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.35 > 1.0 |
| NWC/Revenue: 8.56% < 20% (prev 17.29%; Δ -8.74% < -1%) |
| CFO/TA 0.06 > 3% & CFO 6.72b > Net Income -198.0m |
| Net Debt (33.74b) to EBITDA (6.10b): 5.53 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (982.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 56.35% > 18% (prev 0.57%; Δ 5578 % > 0.5%) |
| Asset Turnover: 43.44% > 50% (prev 43.70%; Δ -0.26% > 0%) |
| Interest Coverage Ratio: 1.03 > 6 (EBITDA TTM 6.10b / Interest Expense TTM 1.83b) |
Altman Z'' 0.93
| A: 0.04 (Total Current Assets 32.88b - Total Current Liabilities 28.96b) / Total Assets 104.21b |
| B: 0.08 (Retained Earnings 8.80b / Total Assets 104.21b) |
| C: 0.02 (EBIT TTM 1.88b / Avg Total Assets 105.58b) |
| D: 0.27 (Book Value of Equity 20.12b / Total Liabilities 74.51b) |
| Altman-Z'' Score: 0.93 = BB |
Beneish M -2.96
| DSRI: 1.17 (Receivables 11.86b/10.31b, Revenue 45.87b/46.74b) |
| GMI: 1.01 (GM 56.35% / 57.14%) |
| AQI: 1.00 (AQ_t 0.56 / AQ_t-1 0.57) |
| SGI: 0.98 (Revenue 45.87b / 46.74b) |
| TATA: -0.07 (NI -198.0m - CFO 6.72b) / TA 104.21b) |
| Beneish M-Score: -2.96 (Cap -4..+1) = A |
What is the price of BAYN shares?
Over the past week, the price has changed by +2.78%, over one month by +20.40%, over three months by +72.76% and over the past year by +116.87%.
Is BAYN a buy, sell or hold?
What are the forecasts/targets for the BAYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.1 | -8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 53.8 | 17.6% |
BAYN Fundamental Data Overview February 07, 2026
P/E Forward = 8.643
P/S = 0.9599
P/B = 1.4996
P/EG = 4.7193
Revenue TTM = 45.87b EUR
EBIT TTM = 1.88b EUR
EBITDA TTM = 6.10b EUR
Long Term Debt = 32.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 6.93b EUR (from shortTermDebt, last quarter)
Debt = 39.64b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 33.74b EUR (from netDebt column, last quarter)
Enterprise Value = 77.77b EUR (44.03b + Debt 39.64b - CCE 5.90b)
Interest Coverage Ratio = 1.03 (Ebit TTM 1.88b / Interest Expense TTM 1.83b)
EV/FCF = 19.75x (Enterprise Value 77.77b / FCF TTM 3.94b)
FCF Yield = 5.06% (FCF TTM 3.94b / Enterprise Value 77.77b)
FCF Margin = 8.58% (FCF TTM 3.94b / Revenue TTM 45.87b)
Net Margin = -0.43% (Net Income TTM -198.0m / Revenue TTM 45.87b)
Gross Margin = 56.35% ((Revenue TTM 45.87b - Cost of Revenue TTM 20.02b) / Revenue TTM)
Gross Margin QoQ = 55.41% (prev 59.36%)
Tobins Q-Ratio = 0.75 (Enterprise Value 77.77b / Total Assets 104.21b)
Interest Expense / Debt = 1.92% (Interest Expense 762.0m / Debt 39.64b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 1.41b (EBIT 1.88b * (1 - 25.00%))
Current Ratio = 1.14 (Total Current Assets 32.88b / Total Current Liabilities 28.96b)
Debt / Equity = 1.34 (Debt 39.64b / totalStockholderEquity, last quarter 29.58b)
Debt / EBITDA = 5.53 (Net Debt 33.74b / EBITDA 6.10b)
Debt / FCF = 8.57 (Net Debt 33.74b / FCF TTM 3.94b)
Total Stockholder Equity = 31.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.19% (Net Income -198.0m / Total Assets 104.21b)
RoE = -0.64% (Net Income TTM -198.0m / Total Stockholder Equity 31.08b)
RoCE = 2.95% (EBIT 1.88b / Capital Employed (Equity 31.08b + L.T.Debt 32.71b))
RoIC = 3.45% (NOPAT 1.41b / Invested Capital 40.94b)
WACC = 3.86% (E(44.03b)/V(83.67b) * Re(6.04%) + D(39.64b)/V(83.67b) * Rd(1.92%) * (1-Tc(0.25)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.00%
[DCF Debug] Terminal Value 82.63% ; FCFF base≈4.13b ; Y1≈3.04b ; Y5≈1.75b
Fair Price DCF = 21.12 (EV 54.49b - Net Debt 33.74b = Equity 20.75b / Shares 982.4m; r=5.90% [WACC]; 5y FCF grow -31.08% → 2.90% )
EPS Correlation: -52.73 | EPS CAGR: -59.56% | SUE: -2.07 | # QB: 0
Revenue Correlation: -37.20 | Revenue CAGR: -3.68% | SUE: -0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.37 | Chg30d=+0.244 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=4.78 | Chg30d=+0.014 | Revisions Net=+1 | Growth EPS=-0.0% | Growth Revenue=+0.6%